Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Maharashtra"

173 News Found

Fredun Pharmaceuticals to launch advanced functional foods plant
News | November 28, 2024

Fredun Pharmaceuticals to launch advanced functional foods plant

The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India


Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
News | November 16, 2024

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24


KIMS to acquire 3,000 beds in next 5 years in Kerala
Healthcare | November 07, 2024

KIMS to acquire 3,000 beds in next 5 years in Kerala

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode


Privi Speciality Chemicals gets USFDA certificate for camphor product
News | October 11, 2024

Privi Speciality Chemicals gets USFDA certificate for camphor product

The company can now expand its business horizon into the area of pharmaceutical applications in the USA


Aster DM Healthcare to launch the Rs. 220 crore Women & Children’s Hospital in Hyderabad
Healthcare | September 22, 2024

Aster DM Healthcare to launch the Rs. 220 crore Women & Children’s Hospital in Hyderabad

The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care


Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Drug Approval | September 22, 2024

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations


Briefs: RPG Life Sciences and Lasa Supergenerics
News | September 14, 2024

Briefs: RPG Life Sciences and Lasa Supergenerics

Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline


Wanbury receives EIR from FDA for Patalganga facility
Drug Approval | August 23, 2024

Wanbury receives EIR from FDA for Patalganga facility

USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation


Wanbury bags safety awards for its API manufacturing site in Patalganga
News | August 22, 2024

Wanbury bags safety awards for its API manufacturing site in Patalganga

These accolades highlight our unwavering commitment to maintaining the highest safety standards